CYTK
Cytokinetics, Incorporated NASDAQ Listed Apr 30, 2004$78.78
+0.86%
vs $78.11
Mkt Cap $9.5B
52w Low $32.43
100.0% of range
52w High $78.78
50d MA $70.93
200d MA $63.72
P/E (TTM)
-12.1x
EV/EBITDA
—
P/B
—
Debt/Equity
-1.9x
ROE
119.0%
P/FCF
-17.7x
RSI (14)
53.90
ATR (14)
$3.20
Beta
0.48
50d MA
$70.93
200d MA
$63.72
Avg Volume
2.4M
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
350 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | -1.67 | -1.67 | +0.0% | 77.09 | +1.7% | -2.9% | -0.7% | +3.5% | -3.1% | +0.3% | — |
| Feb 24, 2026 | AMC | -1.48 | -1.50 | -1.4% | 70.10 | -2.8% | -10.3% | -0.4% | -0.7% | -1.3% | -1.2% | — |
| Nov 5, 2025 | AMC | -1.59 | -1.54 | +3.1% | 59.19 | -0.6% | +1.9% | -0.2% | +3.4% | +6.9% | -0.8% | — |
| Aug 7, 2025 | AMC | -1.34 | -1.12 | +16.4% | 35.25 | +1.7% | -3.2% | -2.6% | +3.2% | +7.5% | +5.0% | — |
| May 6, 2025 | AMC | -1.41 | -1.36 | +3.5% | 33.97 | +4.0% | -2.7% | -1.7% | -2.4% | +1.4% | -4.7% | — |
| Feb 27, 2025 | AMC | -1.29 | -1.26 | +2.3% | 47.45 | -6.5% | -3.1% | -6.8% | +1.9% | +0.4% | -1.4% | — |
| Nov 6, 2024 | AMC | -1.27 | -1.36 | -7.1% | 55.50 | -0.9% | +0.6% | +3.8% | +1.1% | -4.1% | -0.4% | — |
| Aug 8, 2024 | AMC | -1.02 | -1.31 | -28.4% | 54.00 | -3.7% | +3.3% | +0.7% | -0.2% | -0.3% | +2.1% | — |
| May 8, 2024 | AMC | -1.16 | -1.33 | -14.7% | 65.27 | +4.5% | -1.9% | -3.0% | -6.8% | +2.5% | +1.9% | — |
| Feb 27, 2024 | AMC | -1.03 | -1.38 | -34.0% | 80.99 | -3.8% | -9.8% | -1.2% | +2.4% | -8.5% | -1.8% | — |
| Nov 2, 2023 | AMC | -0.72 | -1.35 | -87.5% | 34.64 | +2.3% | +4.8% | -5.2% | +4.1% | -3.0% | -4.7% | — |
| Aug 3, 2023 | AMC | -1.23 | -1.34 | -8.9% | 31.70 | +0.9% | +4.7% | -5.5% | +1.9% | -0.5% | +2.2% | — |
| May 4, 2023 | AMC | -1.24 | -1.38 | -11.3% | 39.29 | +4.3% | +0.4% | -2.6% | +1.1% | +1.0% | -3.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | Citigroup | Initiates | Buy | $99 | $75.18 | $75.65 | +0.6% | +1.7% | +3.0% | -0.9% | -1.4% | -0.8% |
| Apr 6 | Barclays | Maintains | Overweight → Overweight | — | $66.73 | $66.09 | -1.0% | -2.7% | +0.8% | +0.4% | -1.8% | +0.7% |
| Mar 18 | Mizuho | Maintains | Outperform → Outperform | — | $62.13 | $61.50 | -1.0% | +0.1% | +1.2% | -2.0% | -1.2% | -1.5% |
| Mar 17 | JP Morgan | Maintains | Overweight → Overweight | — | $60.83 | $60.94 | +0.2% | +2.1% | +0.1% | +1.2% | -2.0% | -1.2% |
| Mar 6 | UBS | Maintains | Neutral → Neutral | — | $62.19 | $61.38 | -1.3% | -2.9% | +3.3% | +2.9% | -0.9% | -5.7% |
| Feb 26 | Leerink Partners | Maintains | Outperform → Outperform | — | $62.89 | $62.61 | -0.4% | -0.4% | -0.7% | -1.3% | -1.2% | +2.6% |
| Feb 25 | Citizens | Maintains | Market Outperform → Market Outperform | — | $70.10 | $68.12 | -2.8% | -10.3% | -0.4% | -0.7% | -1.3% | -1.2% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $70.10 | $68.12 | -2.8% | -10.3% | -0.4% | -0.7% | -1.3% | -1.2% |
| Feb 20 | RBC Capital | Maintains | Outperform → Outperform | — | $67.83 | $67.72 | -0.2% | +0.2% | +0.5% | +2.7% | -10.3% | -0.4% |
| Feb 3 | Truist | Maintains | Buy → Buy | — | $65.16 | $65.86 | +1.1% | -0.7% | -1.9% | -5.2% | +3.5% | +1.6% |
| Jan 21 | B. Riley Securities | Maintains | Buy → Buy | — | $63.78 | $64.69 | +1.4% | -1.2% | +3.0% | -2.3% | -0.3% | +1.3% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $63.78 | $64.69 | +1.4% | -1.2% | +3.0% | -2.3% | -0.3% | +1.3% |
| Jan 20 | JP Morgan | Maintains | Overweight → Overweight | — | $62.58 | $61.89 | -1.1% | +1.9% | -1.2% | +3.0% | -2.3% | -0.3% |
| Dec 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $65.60 | $64.97 | -1.0% | -3.5% | +1.4% | -1.7% | -2.2% | -0.6% |
| Dec 22 | Needham | Maintains | Buy → Buy | — | $62.72 | $64.00 | +2.0% | +4.6% | -3.5% | +1.4% | -1.7% | -2.2% |
| Dec 22 | RBC Capital | Maintains | Outperform → Outperform | — | $62.72 | $64.00 | +2.0% | +4.6% | -3.5% | +1.4% | -1.7% | -2.2% |
| Dec 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.72 | $64.00 | +2.0% | +4.6% | -3.5% | +1.4% | -1.7% | -2.2% |
| Dec 22 | Citizens | Maintains | Market Outperform → Market Outperform | — | $62.72 | $64.00 | +2.0% | +4.6% | -3.5% | +1.4% | -1.7% | -2.2% |
| Dec 22 | Barclays | Maintains | Overweight → Overweight | — | $62.72 | $64.00 | +2.0% | +4.6% | -3.5% | +1.4% | -1.7% | -2.2% |
| Dec 19 | Goldman Sachs | Upgrade | Neutral → Buy | — | $62.20 | $62.93 | +1.2% | +0.8% | +4.6% | -3.5% | +1.4% | -1.7% |
| Dec 12 | Needham | Maintains | Buy → Buy | — | $60.77 | $60.99 | +0.4% | +4.2% | -1.9% | -0.2% | -3.5% | +4.0% |
| Nov 11 | RBC Capital | Maintains | Outperform → Outperform | — | $62.20 | $62.16 | -0.1% | +6.9% | -0.8% | -0.6% | +1.4% | +0.8% |
| Nov 10 | B. Riley Securities | Maintains | Buy → Buy | — | $60.16 | $60.30 | +0.2% | +3.4% | +6.9% | -0.8% | -0.6% | +1.4% |
| Oct 6 | Barclays | Maintains | Overweight → Overweight | — | $56.97 | $57.87 | +1.6% | +6.4% | -0.8% | +1.1% | -0.8% | -0.4% |
| Oct 2 | BofA Securities | Maintains | Neutral → Neutral | — | $55.84 | $56.16 | +0.6% | +0.9% | +1.2% | +6.4% | -0.8% | +1.1% |
| Sep 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.40 | $50.19 | -0.4% | +6.9% | +2.0% | +1.6% | +0.9% | +1.2% |
| Sep 22 | B. Riley Securities | Maintains | Buy → Buy | — | $48.66 | $48.99 | +0.7% | -0.8% | +0.6% | -0.5% | -1.0% | +5.4% |
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.66 | $48.99 | +0.7% | -0.8% | +0.6% | -0.5% | -1.0% | +5.4% |
| Sep 3 | Barclays | Maintains | Overweight → Overweight | — | $49.62 | $49.90 | +0.6% | +0.7% | -0.5% | +6.6% | -1.7% | -1.1% |
| Sep 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $49.62 | $49.90 | +0.6% | +0.7% | -0.5% | +6.6% | -1.7% | -1.1% |
| Sep 2 | Citigroup | Maintains | Buy → Buy | — | $35.33 | $44.91 | +27.1% | +40.4% | +0.7% | -0.5% | +6.6% | -1.7% |
| Sep 2 | Needham | Maintains | Buy → Buy | — | $35.33 | $44.91 | +27.1% | +40.4% | +0.7% | -0.5% | +6.6% | -1.7% |
| Sep 2 | Stifel | Maintains | Buy → Buy | — | $35.33 | $44.91 | +27.1% | +40.4% | +0.7% | -0.5% | +6.6% | -1.7% |
| Sep 2 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $35.33 | $44.91 | +27.1% | +40.4% | +0.7% | -0.5% | +6.6% | -1.7% |
| Aug 8 | Citigroup | Maintains | Buy → Buy | — | $35.25 | $35.85 | +1.7% | -3.2% | -2.6% | +3.2% | +7.5% | +5.0% |
| Jun 9 | JP Morgan | Maintains | Overweight → Overweight | — | $32.30 | $32.95 | +2.0% | +2.6% | +4.3% | -4.1% | +0.3% | +3.6% |
| May 29 | Mizuho | Maintains | Outperform → Outperform | — | $30.28 | $30.23 | -0.2% | +3.4% | -1.0% | +0.6% | +2.5% | +1.3% |
| May 14 | Needham | Maintains | Buy → Buy | — | $30.61 | $30.50 | -0.4% | -2.0% | -0.5% | +3.9% | -0.8% | +6.2% |
| May 8 | Barclays | Maintains | Overweight → Overweight | — | $33.04 | $32.76 | -0.8% | -1.7% | -2.4% | +1.4% | -4.7% | -2.0% |
| May 7 | RBC Capital | Maintains | Outperform → Outperform | — | $33.97 | $35.34 | +4.0% | -2.7% | -1.7% | -2.4% | +1.4% | -4.7% |
| May 7 | Citigroup | Maintains | Buy → Buy | — | $33.97 | $35.34 | +4.0% | -2.7% | -1.7% | -2.4% | +1.4% | -4.7% |
| May 2 | UBS | Maintains | Neutral → Neutral | — | $42.92 | $37.67 | -12.2% | -13.0% | -1.8% | -7.4% | -2.7% | -1.7% |
| May 2 | Needham | Maintains | Buy → Buy | — | $42.92 | $37.67 | -12.2% | -13.0% | -1.8% | -7.4% | -2.7% | -1.7% |
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.48 | $38.90 | -1.5% | -3.9% | -0.3% | +0.5% | +6.1% | +0.2% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.81 | $38.91 | -2.3% | -3.1% | +1.5% | +0.8% | -3.9% | -0.3% |
| Apr 15 | BofA Securities | Maintains | Neutral → Neutral | — | $39.81 | $38.91 | -2.3% | -3.1% | +1.5% | +0.8% | -3.9% | -0.3% |
| Apr 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $37.32 | $36.20 | -3.0% | +1.4% | +2.1% | +3.0% | -3.1% | +1.5% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $35.99 | $36.52 | +1.5% | -3.9% | +8.0% | +1.4% | +2.1% | +3.0% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.52 | $40.44 | -0.2% | -7.8% | -3.7% | -3.9% | +8.0% | +1.4% |
| Apr 3 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $40.25 | $39.43 | -2.0% | +0.7% | -7.8% | -3.7% | -3.9% | +8.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Blum Robert IDir/Off | President & CEO | Sell | 7,500 | $70.46 | $528K | 385,330 | +5.37% | — |
| Jun 9, 2026 | Malik Fady IbrahamOff | EVP Research & Development | Sell | 3,500 | $67.98 | $238K | 153,902 | -2.02% | +5.37% |
| Jun 1, 2026 | PARSHALL B LYNNEDir | — | Sell | 5,000 | $74.08 | $370K | 15,784 | -3.76% | -5.01% |
| Jun 1, 2026 | Callos AndrewOff | EVP, Chief Commercial Officer | Sell | 15,000 | $74.08 | $1.1M | 58,555 | -3.76% | -5.01% |
| Jun 1, 2026 | Kaye Edward M. MDDir | — | Sell | 2,933 | $76.09 | $223K | 10,283 | -3.76% | -5.01% |
| May 27, 2026 | Blum Robert IDir/Off | President & CEO | Sell | 7,500 | $77.21 | $579K | 392,830 | -0.07% | +2.23% |
| May 19, 2026 | Malik Fady IbrahamOff | EVP Research & Development | Sell | 3,500 | $75.69 | $265K | 153,902 | -0.90% | -0.44% |
| May 14, 2026 | Blum Robert IDir/Off | President & CEO | Sell | 7,500 | $77.92 | $584K | 400,330 | -3.55% | -0.90% |
| May 5, 2026 | Malik Fady IbrahamOff | EVP Research & Development | Sell | 3,500 | $77.37 | $271K | 153,902 | -2.92% | +0.34% |
| May 5, 2026 | WIERENGA WENDELLDir | — | Sell | 4,032 | $75.00 | $302K | 32,637 | -2.92% | +0.34% |
| May 5, 2026 | HENDERSON JOHN TDir | — | Sell | 20,000 | $75.97 | $1.5M | 75,237 | -2.92% | +0.34% |
| May 5, 2026 | Lee SungOff | EVP, Chief Financial Officer | Sell | 23,906 | $76.87 | $1.8M | 63,221 | -2.92% | +0.34% |
| May 5, 2026 | Callos AndrewOff | EVP, Chief Commercial Officer | Sell | 11,333 | $77.25 | $875K | 58,555 | -2.92% | +0.34% |
| May 1, 2026 | Callos AndrewOff | EVP, Chief Commercial Officer | Sell | 15,857 | $65.00 | $1.0M | 58,555 | +16.71% | -3.06% |
| Apr 30, 2026 | Callos AndrewOff | EVP, Chief Commercial Officer | Sell | 15,000 | $63.26 | $949K | 58,555 | -0.97% | -0.73% |
| Apr 29, 2026 | Blum Robert IDir/Off | President & CEO | Sell | 7,500 | $59.62 | $447K | 407,830 | +7.37% | -2.92% |
8-K
Cytokinetics, Incorporated -- 8-K Filing
I cannot provide a meaningful analysis based on this filing summary, as it contains only technical XBRL metadata and references without substantive business information about Cytokinetics.
May 27
8-K
Cytokinetics, Incorporated -- 8-K Filing
May 8
8-K
Cytokinetics Inc. -- 8-K Filing
Cytokinetics' MYQORZO received regulatory approvals across the U.S., China, and Europe for symptomatic obstructive hypertrophic cardiomyopathy, with U.S. commercialization launching immediately and multiple pipeline catalysts expected through 2026.
Feb 24
8-K · 8.01
!! High
Cytokinetics Inc. -- 8-K 8.01: Material Event / Announcement
Cytokinetics received European Commission approval for MYQORZO (aficamten) to treat obstructive hypertrophic cardiomyopathy, expanding the company's commercial opportunities in a major market.
Feb 17
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 10,723,140 | $707M | Reduced | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 5,843,782 | $385M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 5,488,634 | $362M | New | Mar 2026 |
| 4 | Avoro Capital Advisors Llc | 3,333,333 | $220M | New | Mar 2026 |
| 5 | Bank Of America Corp /de/ | 3,125,436 | $206M | Added | Mar 2026 |
| 6 | Rtw Investments, Lp | 2,721,158 | $179M | — | Mar 2026 |
| 7 | Morgan Stanley | 2,530,602 | $161M | Reduced | Dec 2025 |
| 8 | Ubs Group Ag | 2,077,277 | $137M | Added | Mar 2026 |
| 9 | Northern Trust Corp | 1,441,634 | $95M | Added | Mar 2026 |
| 10 | Citadel Advisors Llc | 1,099,858 | $72M | Reduced | Mar 2026 |
| 11 | William Blair Investment Management, Llc | 1,087,591 | $72M | New | Mar 2026 |
| 12 | Bank Of New York Mellon Corp | 1,006,185 | $66M | Added | Mar 2026 |
| 13 | Woodline Partners Lp | 1,000,428 | $66M | Reduced | Mar 2026 |
| 14 | Royalty Pharma Sub-Manager, Llc | 980,392 | $65M | — | Mar 2026 |
| 15 | Principal Financial Group Inc | 976,892 | $62M | Reduced | Dec 2025 |
| 16 | Susquehanna International Group, Llp | 898,951 | $59M | Added | Mar 2026 |
| 17 | Jpmorgan Chase & Co | 903,805 | $57M | Reduced | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 854,374 | $56M | Added | Mar 2026 |
| 19 | Melqart Asset Management (Uk) Ltd | 843,949 | $56M | Added | Mar 2026 |
| 20 | Qube Research & Technologies Ltd | 779,446 | $51M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$9.46B
Enterprise Value
$9.70B
P/E (TTM)
-12.05x
Forward P/E
—
PEG Ratio
-0.40x
P/B
—
P/S
107.47x
P/FCF
-17.69x
EV/EBITDA
—
Shares Out
120.1M
Financials (TTM)
Revenue
$88.0M
Net Income
-$785.0M
EBITDA
-$775.3M
Free Cash Flow
-$534.8M
Op Cash Flow
-$510.0M
EPS Basic
$-6.54
EPS Diluted
$-6.54
EPS Forward
$-6.50
Gross Margin
88.5%
Op Margin
-695.4%
Net Margin
-891.6%
Balance Sheet
Total Assets
$1.42B
Total Liab.
$2.08B
Total Equity
-$659.6M
Cash
$882.2M
LT Debt
$1.12B
Book Value/Sh
$-5.50
Debt/Equity
-1.95x
Current Ratio
4.53
Quick Ratio
4.53
Returns & Growth
ROE
119.0%
ROA
-55.1%
ROIC
-47.7%
Rev Growth YoY
+376.6%
EPS Growth YoY
-24.3%
Price Returns
2W
-2.4%
1M
+20.0%
3M
+23.4%
6M
+12.7%
12M
+147.5%
Technicals
52W High
$78.78
52W Low
$32.43
50d MA
$70.93
200d MA
$63.72
RSI (14)
53.90
ATR (14)
$3.20
Beta
0.48
Avg Volume
2.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$92.50
High
$136.00
Low
$69.00
Median
$90.00
Data updated apr 25, 2026 4:28am
· Source: financialmodelingprep.com